Abstract
l-DOPA induced dyskinesias (LIDs) may affect up to 40% of Parkinson’s disease (PD) and impact negatively health-related quality of life. Amantadine has demonstrated significant antidyskinetic effects in animal PD models and in randomized double-blind placebo-controlled trials (RCTs) in patients with PD. These effects are thought to be related to the blockade of NMDA receptors modulating cortico-striatal glutamatergic–dopaminergic interactions involved in the genesis of LIDs. There are three pharmaceutical forms of amantadine currently available in the market: an oral immediate-release (IR) formulation, which is widely available; an extended-release (ER) formulation (ADS-5102) which has been recently developed and approved by the FDA; and an intravenous infusion (IV) solution, which is not commonly used in clinical practice. RCTs with amantadine IR or ER, involving more than 650 patients have shown consistent and long-lasting reductions in LIDs. Interestingly, ADS-5102 not only reduced LIDs, but also reduced significantly at the same time the duration of daily OFF-time, a unique finding compared with other antiparkinsonian medications that usually reduce time spent OFF at the cost of worsening of LIDs. Amantadine IR might also have possible effects on other PD symptoms such as apathy or fatigue. The most common adverse reactions with amantadine are constipation, cardiovascular dysfunction including QT prolongation, orthostatic hypotension and edema, neuropsychiatric symptoms such as hallucinations, confusion and delirium, nausea and livedo reticularis. Corneal degeneration is rare but critical. In summary, amantadine immediate and extended-release are effective and safe for the treatment of LIDs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adamas Pharmaceuticals (2017) Summary of product characteristics: Gocovri, amantadine extended-release. https://www.gocovri.com/. Accessed 02 Oct 2017
Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448–458
Allers KA, Bergstrom DA, Ghazi LJ, Kreiss DS, Walters JR (2005) MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson’s disease. Exp Neurol 191(1):104–118. https://doi.org/10.1016/j.expneurol.2004.08.030
Alliance Pharmaceuticals (2010) Summary of product characteristics: Symmetrel(R) capsules (amantadine hydrochloride 100 mg)
Alonso Navarro H, Sanz-Aiz A, Izquierdo L, Jimenez Jimenez FJ (2009) Syndrome of inappropriate antidiuretic hormone secretion possibly associated with amantadine therapy in Parkinson disease. Clin Neuropharmacol 32(3):167–168. https://doi.org/10.1097/WNF.0b013e3181900115
Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14(1):35–51. https://doi.org/10.2165/00003088-198814010-00003
Aron Badin R, Spinnewyn B, Gaillard MC, Jan C, Malgorn C, Van Camp N, Dolle F, Guillermier M, Boulet S, Bertrand A, Savasta M, Auguet M, Brouillet E, Chabrier PE, Hantraye P (2013) IRC-082451, a novel multitargeting molecule, reduces l-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PLoS ONE 8(1):e52680. https://doi.org/10.1371/journal.pone.0052680
Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, Carta M (2013) Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 28(8):1088–1096. https://doi.org/10.1002/mds.25366
Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196(2):422–429. https://doi.org/10.1016/j.expneurol.2005.08.017
Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem 118(6):1043–1055. https://doi.org/10.1111/j.1471-4159.2011.07376.x
Birkmayer W, Hornykiewicz O (1998) The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 4(2):59–60
Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13(5):798–802. https://doi.org/10.1002/mds.870130507
Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25(13):3312–3322. https://doi.org/10.1523/JNEUROSCI.4262-04.2005
Bortolanza M, Bariotto-Dos-Santos KD, Dos-Santos-Pereira M, da-Silva CA, Del-Bel E (2016) Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson’s disease. Neurotox Res 30(1):88–100. https://doi.org/10.1007/s12640-016-9618-4
Boyd JT, Silverman DA (2013) Amantadine-induced patulous eustachian tubes in Parkinson’s disease. Case Rep Otolaryngol 2013:426413. https://doi.org/10.1155/2013/426413
Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson’s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236(3):153–156
Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B (2015) Levodopa-induced plasticity: a double-edged sword in Parkinson’s disease? Philos Trans R Soc Lond B Biol Sci. https://doi.org/10.1098/rstb.2014.0184
Calabresi P, Pisani A, Rothwell J, Ghiglieri V, Obeso JA, Picconi B (2016) Hyperkinetic disorders and loss of synaptic downscaling. Nat Neurosci 19(7):868–875. https://doi.org/10.1038/nn.4306
Cattoni J, Parekh R (2014) Acute respiratory distress syndrome: a rare presentation of amantadine toxicity. Am J Case Rep 15:1–3. https://doi.org/10.12659/ajcr.889931
Chang KC, Jeong JH, Kim MK, Wee WR, Lee JH, Jeon BS (2010) The effect of amantadine on corneal endothelium in subjects with Parkinson’s disease. Ophthalmology 117(6):1214–1219. https://doi.org/10.1016/j.ophtha.2009.10.039
Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23(10 Suppl):S86–S91
Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474
Cheng PL, Hung SW, Lin LW, Chong CF, Lau CI (2008) Amantadine-induced serotonin syndrome in a patient with renal failure. Am J Emerg Med 26(1):112.e115–116.e115. https://doi.org/10.1016/j.ajem.2007.07.015
da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM (2005) Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 11(7):449–452. https://doi.org/10.1016/j.parkreldis.2005.05.008
Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF, Richter RR, Means ED (2000) Evaluation of a measurement strategy for Parkinson’s disease: assessing patient health-related quality of life. Qual Life Res 9(1):87–100
Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P (1999) Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34(4):313–318 (https://doi.org/10.1002/(SICI)1098-2396(19991215)34:4<313:AID-SYN7>3.0.CO;2-1)
Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76–89. https://doi.org/10.1016/j.bbr.2007.01.013
Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16(3):515–520
Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 41(4):261–309. https://doi.org/10.2165/00003088-200241040-00003
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508
Faulkner MA (2014) Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opin Drug Saf 13(8):1055–1069. https://doi.org/10.1517/14740338.2014.931369
Fisher A, Biggs CS, Starr MS (1998) Effects of glutamate antagonists on the activity of aromatic l-amino acid decarboxylase. Amino Acids 14(1–3):43–49
Foller M, Geiger C, Mahmud H, Nicolay J, Lang F (2008) Stimulation of suicidal erythrocyte death by amantadine. Eur J Pharmacol 581(1–2):13–18. https://doi.org/10.1016/j.ejphar.2007.11.051
Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S2–41. https://doi.org/10.1002/mds.23829
Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, Revuelta GJ, Short EB (2017) The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. J Psychiatr Pract 23(3):191–199. https://doi.org/10.1097/pra.0000000000000237
Goetz CG (1998) New lessons from old drugs: amantadine and Parkinson’s disease. Neurology 50(5):1211–1212
Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S (2013) Which dyskinesia scale best detects treatment response? Mov Disord 28(3):341–346. https://doi.org/10.1002/mds.25321
Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA (2017) Topiramate as an adjunct to amantadine in the treatment of dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled multicenter study. Mov Disord. https://doi.org/10.1002/mds.27092
Goralski KB, Smyth DD, Sitar DS (1999) In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport. J Pharmacol Exp Ther 290(2):496–504
Grace AA (2008) Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 23(Suppl 3):S560–S569. https://doi.org/10.1002/mds.22020
Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Frassdorf M (2014) Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis 2014:467131. https://doi.org/10.1155/2014/467131
Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ (2017) ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 2 study): interim results of an open-label safety study. J Parkinsons Dis 7(3):511–522. https://doi.org/10.3233/jpd-171134
Heikkila RE, Cohen G (1972) Evaluation of amantadine as a releasing agent or uptake blocker for H 3-dopamine in rat brain slices. Eur J Pharmacol 20(2):156–160
Hesselink MB, De Boer AG, Breimer DD, Danysz W (1999) Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. J Neural Transm (Vienna) 106(5–6):409–421. https://doi.org/10.1007/s007020050168
Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson’s disease. J Pharmacol Exp Ther 310(1):386–394. https://doi.org/10.1124/jpet.104.066191
Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, Stephens MK, Prati RC, Brater DC (1981) Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 94(4 pt 1):454–458
Hubsher G, Haider M, Okun MS (2012) Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78(14):1096–1099. https://doi.org/10.1212/WNL.0b013e31824e8f0d
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of l-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 65(1):171–222. https://doi.org/10.1124/pr.111.005678
Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320:21–42
Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM (2013) TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73:337–347. https://doi.org/10.1016/j.neuropharm.2013.06.005
Kaefer V, Semedo JG, Silva Kahl VF, Von Borowsky RG, Gianesini J, Ledur Kist TB, Pereira P, Picada JN (2010) DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. J Appl Toxicol 30(8):745–753. https://doi.org/10.1002/jat.1550
Kataoka H, Ueno S (2011) Dropped head associated with amantadine in Parkinson disease. Clin Neuropharmacol 34(1):48–49. https://doi.org/10.1097/WNF.0b013e318204d35c
Kim YE, Yun JY, Yang HJ, Kim HJ, Kim MK, Wee WR, Jeon BS (2013) Amantadine induced corneal edema in a patient with primary progressive freezing of gait. J Mov Disord 6(2):34–36. https://doi.org/10.14802/jmd.13008
Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF (2014) Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson’s disease. Mov Disord 29(6):772–779. https://doi.org/10.1002/mds.25859
Kobylecki C, Hill MP, Crossman AR, Ravenscroft P (2011) Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson’s disease. Mov Disord 26(13):2354–2363. https://doi.org/10.1002/mds.23867
Kong M, Ba M, Ren C, Yu L, Dong S, Yu G, Liang H (2017) An updated meta-analysis of amantadine for treating dyskinesia in Parkinson’s disease. Oncotarget. https://doi.org/10.18632/oncotarget.17622
Koppel C, Tenczer J (1985) A revision of the metabolic disposition of amantadine. Biomed Mass Spectrom 12(9):499–501
Korchounov A, Kessler KR, Schipper HI (2004) Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson’s disease. Acta Neurol Scand 109(1):45–51
Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206(4):297–300
Koziorowski D, Friedman A (2007) Levodopa “drug holiday” with amantadine infusions as a treatment of complications in Parkinson’s disease. Mov Disord 22(7):1033–1036. https://doi.org/10.1002/mds.21448
Kubo S, Iwatake A, Ebihara N, Murakami A, Hattori N (2008) Visual impairment in Parkinson’s disease treated with amantadine: case report and review of the literature. Parkinsonism Relat Disord 14(2):166–169. https://doi.org/10.1016/j.parkreldis.2007.03.003
Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339(15):1044–1053
Lee PY, Tu HP, Lin CP, Chang CH, Cheng KC, Lin CC, Hsu SL (2016) Amantadine use as a risk factor for corneal edema: a nationwide cohort study in Taiwan. Am J Ophthalmol 171:122–129. https://doi.org/10.1016/j.ajo.2016.08.034
Luginger E, Wenning GK, Bosch S, Poewe W (2000) Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 15(5):873–878
Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194(1):66–75. https://doi.org/10.1016/j.expneurol.2005.02.002
Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-d-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263(2):717–724
Marxreiter F, Winkler J, Uhl M, Madzar D (2017) A case report of severe delirium after amantadine withdrawal. Case Rep Neurol 9(1):44–48. https://doi.org/10.1159/000460814
Matsubayashi H, Swanson KL, Albuquerque EX (1997) Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281(2):834–844
McNamara P, Durso R (1991) Reversible pathologic jealousy (Othello syndrome) associated with amantadine. J Geriatr Psychiatry Neurol 4(3):157–159
Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56(11):1383–1386
Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M (1994) Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res 662(1–2):255–258
Montel S, Bonnet A-M, Bungener C (2009) Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson’s disease. J Geriatr Psychiatry Neurol 22(2):95–102. https://doi.org/10.1177/0891988708328219
Moresco RM, Volonte MA, Messa C, Gobbo C, Galli L, Carpinelli A, Rizzo G, Panzacchi A, Franceschi M, Fazio F (2002) New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET-[(11)C]raclopride study. J Neural Transm 109(10):1265–1274. https://doi.org/10.1007/s00702-002-0694-7
Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M (2009) Plasma amantadine concentrations in patients with Parkinson’s disease. Parkinsonism Relat Disord 15(5):351–353. https://doi.org/10.1016/j.parkreldis.2008.08.005
Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J, Rodriguez M, Olanow CW (2008) The basal ganglia in Parkinson’s disease: current concepts and unexplained observations. Ann Neurol 64(Suppl 2):S30–S46. https://doi.org/10.1002/ana.21481
Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ (2017) Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. https://doi.org/10.1002/mds.27131
Olanow WC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease I (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071. https://doi.org/10.1002/mds.25364
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, Network NS-PC (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82(4):300–307. https://doi.org/10.1212/WNL.0000000000000050
Paci C, Thomas A, Onofrj M (2001) Amantadine for dyskinesia in patients affected by severe Parkinson’s disease. Neurol Sci 22(1):75–76
Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ (2015) Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED study). Mov Disord. https://doi.org/10.1002/mds.26159
Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ (2017) ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.0943
Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A (2012) Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson’s disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci 36(9):3224–3234. https://doi.org/10.1111/j.1460-9568.2012.08243.x
Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996) Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8(3):446–454
Pèchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-voinet C, Berdeaux G, Ziegler M (2005) Effects of dyskinesias in Parkinson’ s disease on quality of life and health-related costs : a prospective European study. Eur J Neurol 12:956–963
Peeters M, Page G, Maloteaux JM, Hermans E (2002) Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res 949(1–2):32–41
Perez-Lloret S, Barrantes FJ (2016) Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. NPJ Parkinson’s Dis 2:16001–16012
Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O (2012) Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord 18(5):501–505. https://doi.org/10.1016/j.parkreldis.2012.01.012
Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, Meissner WG, Tison F, Rascol O, Group CS (2017) l-DOPA-induced dyskinesias, motor fluctuations and Health-related Quality of Life: the COPARK survey. Eur J Neurol. https://doi.org/10.1111/ene.13466
Pimentel L, Hughes B (1991) Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. Pediatr Emerg Care 7(2):89–92
Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590. https://doi.org/10.1002/mds.25945
Quaresma MV, Gomes AC, Serruya A, Vendramini DL, Braga L, Bucard AM (2015) Amantadine-induced livedo reticularis—case report. Ann Bras Dermatol 90(5):745–747. https://doi.org/10.1124/jpet.115.230201 (https://doi.org/10.1590/abd1806-4841.20153394)
Rana AQ, Masroor MS (2012) Patient perception of Levido reticularis due to amantadine. Int J Neurosci 122(7):363–366. https://doi.org/10.3109/00207454.2012.668727
Reichmann H, Emre M (2012) Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone. Expert Rev Neurother 12(2):119–131. https://doi.org/10.1586/ern.11.203
Reis J, John D, Heimeroth A, Mueller HH, Oertel WH, Arndt T, Rosenow F (2006) Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology 31(12):2758–2766. https://doi.org/10.1038/sj.npp.1301122
Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, Athen O, Khne-Volland R, Dodel RC (2007) Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 13(2):108–114. https://doi.org/10.1016/j.parkreldis.2006.07.009
Rohrbacher J, Bijak M, Misgeld U (1994) Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices. Neurosci Lett 182(1):95–98
Ruzicka E, Streitova H, Jech R, Kanovsky P, Roth J, Rektorova I, Mecir P, Hortova H, Bares M, Hejdukova B, Rektor I (2000) Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson’s disease. J Neural Transm (Vienna) 107(11):1297–1306. https://doi.org/10.1007/s007020070019
Sartori M, Pratt CM, Young JB (1984) Torsade de Pointe. Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 77(2):388–391
Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T, Amantadine Study G (2010) Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One 5(12):e15298. https://doi.org/10.1371/journal.pone.0015298
Schwartz M, Patel M, Kazzi Z, Morgan B (2008) Cardiotoxicity after massive amantadine overdose. J Med Toxicol 4(3):173–179
Sebastianutto I, Maslava N, Hopkins CR, Cenci MA (2016) Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. Neurobiol Dis 96:156–170
Seier M, Hiller A (2017) Parkinson’s disease and pregnancy: an updated review. Parkinsonism Relat Disord 40:11–17. https://doi.org/10.1016/j.parkreldis.2017.05.007
Snoey ER, Bessen HA (1990) Acute psychosis after amantadine overdose. Ann Emerg Med 19(6):668–670
Snow BJ, Macdonald L, McAuley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23(2):82–85
Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-d-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213(3):439–443
Takahashi T, Yamashita H, Zhang YX, Nakamura S (1996) Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41(6):363–367
Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(1):141–143
Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404. https://doi.org/10.1002/ana.22029
Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, Thompson W (1995) N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 9(1):49–53
Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN (1998a) Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids 14(1–3):75–82
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5):1323–1326
Volonte MA, Moresco RM, Gobbo C, Messa C, Carpinelli A, Rizzo G, Comi G, Fazio F (2001) A PET study with [11-C]raclopride in Parkinson’s disease: preliminary results on the effect of amantadine on the dopaminergic system. Neurol Sci 22(1):107–108
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E (2009) Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol 8(12):1140–1149. https://doi.org/10.1016/S1474-4422(09)70287-X
Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963–968. https://doi.org/10.1002/ana.22164
Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 25(10):1357–1363. https://doi.org/10.1002/mds.23034
Zifko UA (2004) Management of fatigue in patients with multiple sclerosis. Drugs 64(12):1295–1304
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perez-Lloret, S., Rascol, O. Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. J Neural Transm 125, 1237–1250 (2018). https://doi.org/10.1007/s00702-018-1869-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-018-1869-1